“M3 is the undisputed leader in Japanese digital medical marketing, capitalizing on a long-term shift as pharmaceutical companies cut costs and digitize outreach. While North American restructuring has caused near-term overseas friction, the firm's core platform economics remain highly attractive.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.